Page 31 - Read Online

Cui et al. Treatment guidelines of chronic inflammatory demyelinating polyneuropathy in China

Neurotrophic approaches Patient consent
Mainly vitamin B therapy: B1, B12 (methylcobalamin, There is no patient involved.
adenosine cobalamin), B6, etc. could be included.
Ethics approval
Symptomatic treatment This article does not contain any studies with human
For neuropathic pain, carbamazepine, amitriptyline, participants or animals.
tramadol, gabapentin and pregabalin, etc. could be
prescribed. REFERENCES
Rehabilitation 1. French CIDP Study Group. Recommendations on diagnostic strategies
When the CIDP condition is under controlled, early for chronic inflammatory demyelinating polyradiculoneuropathy. J
start of exercises of neurological rehabilitation can 2. Neurol Neurosurg Psychiatry 2008;79:115-8.
Said G. Chronic inflammatory demyelinating polyneuropathy.
prevent muscle atrophy and contractures. Neuromuscul Disord 2006;16:293-303.
3. Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, Graves
PROGNOSIS M, Gorson K, Hahn AF, Hughes RA, Katz J, Lewis RA, Parry GJ,
van Doorn P, Cornblath DR. Derivation and validation of diagnostic
The prognosis in remission relapsing type of CIDP criteria for chronic inflammatory demyelinating polyneuropathy. J
Neurol Sci 2009;277:1-8.
is better than the chronic progressive type; 70-90% 4. Dyck PJ, Thomas PK. Peripheral Neuropathy. 4th ed. Philadelphia:
of patients can be improved well by immunotherapy, Elsevier Saunders; 2005.
but not in a minor group. In some rare cases, 5. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn
immunotherapy is potent in treatment for a transient A, Illa I, Koski CL, Léger JM, Nobile-Orazio E, Pollard J, Sommer
period, following by the dependence. C, Van den Bergh P, van Doorn PA, van Schaik IN. European
Federation of Neurological Societies/Peripheral Nerve Society
guideline on management of chronic inflammatory demyelinating
The Chinese version of this guideline has been polyradiculoneuropathy: report of a joint task force of the European
published in Chin J Neurol 2010;43:586-8. Federation of Neurological Societies and the Peripheral Nerve
Society. Eur J Neurol 2006;13:326-32.
Acknowledgments 6. Feldman EL, Grisold W, Russell JW, Löscher WN. Atlas of
The authors sincerely thank Prof. Shu-You Fang, Neuromuscular Diseases – A Practical Guideline. New York:
Yu-Pu Guo, De-Xuan Kang, Pei-Gen Kuang, Xiu- 7. Springer; 2004.
Köller H, Schroeter M, Kieseier BC, Hartung HP. Chronic inflammatory
Ling Liang, Zhuo-Lin Liu, Ming-Li Rao, Ding-Guo demyelinating polyneuropathy -- update on pathogenesis, diagnostic
Shen, Xiao-Fu Tang, Li-Juan Wu for the help in the criteria and therapy. Curr Opin Neurol 2005;18:273-8.
preparation of this guideline and recommendations. 8. Elovaara I，Apostolski S，van Doom P，Gilhus NE, Hietaharju
A, Honkaniemi J, van Schaik IN, Scolding N, Soelberg Sørensen P,
Financial support and sponsorship Udd B. EFNS guidelines for the use of intravenous immunoglobulin
None. in treatment of neurological diseases: EFNS task force on the use of
intravenous immunoglobulin in treatment of neurological diseases.
Eur J Neurol 2008;15:893-908.
Conflicts of interest 9. Ropper AH, Brown RH. Adams and Victor’s principles of neurology.
There are no conflicts of interest. 8th ed. Columbus: McGraw-Hill Professional; 2005.

Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ February 20, 2017 23